June 27, 2017

Scientific Advisory Board

MangoGen’s Scientific Advisory Board


Dr. Jean-Claude Tardif CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS 

Dr. Jean-Claude Tardif is the Director of the Research Centre at the Montréal Heart Institute and Professor of Medicine at the University of Montréal. He is the Scientific Director of the Montréal Heart Institute Coordinating Centre and Chairman of the steering committees of the CIHR-funded Canadian Atherosclerosis Imaging Network and Medical Imaging Trials NEtwork of Canada.

His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as large international randomized clinical trials.





Dr. Alain Labbe

Dr. Labbe serves as MangoGen’s Chief Scientific Officer. Alain has a wealth of experience in a variety of disciplines including biochemistry, infectious diseases, probiotics, and virology.




Dr. Giuseppe (Joe) Martucci

Dr. Martucci is an Assistant Professor and practicing interventional cardiologist at McGill University. He is on staff at the McGill University Health Centre (MUHC) and the Sir Mortimer B. Davis Jewish General Hospital. He completed his cardiology core training at McGill University before pursuing his fellowship training in interventional cardiology at the Montreal Heart Institute. This was followed by more advanced training in Interventional Adult Congenital Heart Disease, Pulmonary Hypertension and Valvular Intervention at the Boston Children’s Hospital and Harvard Medical School. His particular research interest involves the design of cardiac valves and molecular biology. He is presently the Director of Interventional Congenital Heart Disease for the MAUDE Unit.

Dr. Satya Prakash Ph.D.

Dr. Prakash is a professor of biomedical engineering at McGill University, QC, Canada. Dr. Prakash leads a research team dedicated to the advancement and development of bio-engineering delivery systems, including targeted controlled-release, targeted drug systems and cell delivery mechanisms. The goal is to design biotherapeutics that are capable of targeting specific cell types, organs or tissues to treat specific medical conditions. Dr. Prakash has had over 150 scientific publications, and 60 approved/pending patent applications. In 2003, Dr. Prakash co-founded Micropharma, a microbiome company based in Montreal, Canada. As Director of Micropharma, Satya has taken scientific discovery through and into the commercial world. Dr. Prakash, is a co-inventor of MangoGen’s patented technology.